HRS-2329 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=80 | Not yet recruiting | Sponsor: Zhejiang University

IO biomarker • New P1/2 trial • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor • RAS